Non-GLP Exploratory Toxicology

Early Assessment of Drug Safety Risk

Capabilities include:

Mechanistic Toxicology Studies

Capabilities include:

  • Histology
  • Haematology and biochemistry
  • mRNA analysis and upregulation in CYP activity
  • Protein expression analysis
  • Toxicogenetics

Proof of Concept for Drug Mechanism of Action or Efficacy

Capabilities include:


Cyprotex eStore

Order our services online.

Visit the Cyprotex eStore

Contact Our Experts

Paul Walker

Paul Walker, PhD

VP Head of Toxicology & Innovation Efficiency

Logo Cyprotex white
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.